Saneca investing €3.5m into small-scale API capabilities

By Staff Reporter

- Last updated on GMT

Image: iStock/hynci
Image: iStock/hynci

Related tags Investment

Saneca Pharma says the expanded capabilities will feed demand for small-scale API batches to support clients’ R&D projects.

The investment will be spread across five suites at Saneca’s site in Hlohovec, Slovakia, bolstering production of its opiate and synthetic drug APIs, and will include a new kilo lab with reactors to make batches from around one to 30 kg.

“This investment into new equipment at our site gives us much greater flexibility in supporting clients with development projects,”​ said CEO Anthony Sheehan. “It also gives companies the option to tech-transfer products in at an earlier stage.”

A spokesperson for the firm told this publication the investment is around €3.5m ($4m).

The news comes on the back of several deals announced by Saneca, including a contract to make more than 20 products for Xantis Pharma​, and an opiate-based intermediate supply deal with AMRI​.

In 2015​, the API maker acquired Ireland’s Suir Pharma, adding finished oral solid dosage forms to its capabilities. Suir has since gone into liquidation​ after Saneca decided it was no longer willing to fund the generics firm.

Related news

Show more

Related products

show more

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more